AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment of the C-terminal region of human growth hormone (HGH). It was originally developed as an anti-obesity drug and has been extensively studied for its potential effects on fat metabolism without promoting cell proliferation or insulin resistance.
AOD-9604’s mechanism of action is thought to specifically target fat cells, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation). It does this by mimicking the effects of the C-terminal fragment of HGH, which is responsible for HGH’s fat-reducing properties, but without interacting with the GH receptor in a way that would lead to increased IGF-1 levels or other broader HGH effects.
Clinical and preclinical research has explored AOD-9604 in the context of:
Its selective action on fat cells and lack of impact on glucose metabolism make it a subject of considerable interest for targeted fat-loss research.
AOD-9604’s regulatory status may vary depending on jurisdiction and current policy. In many regions, it is considered a research chemical and is not approved for human therapeutic use. Researchers should consult the latest guidelines from regulatory bodies like the FDA in the US or EMA in Europe for specific guidance. For a general overview, refer to our U.S. peptide legal status tracker.
Researchers comparing AOD-9604 products often evaluate:
PeptideChecker tracks AOD-9604 product listings across multiple suppliers to help researchers compare availability, pricing, and quality.
Q: What is AOD-9604 primarily used for in research? A: AOD-9604 is extensively studied for its potential roles in fat metabolism, stimulating lipolysis and inhibiting lipogenesis.
Q: How is AOD-9604 typically administered in research settings? A: Common administration routes in research include subcutaneous injection.
Q: Where can I find verified suppliers for AOD-9604? A: Our supplier comparison tool provides a list of vendors offering AOD-9604 with purity and pricing details.
\n\n